PAVmed (PAVM) to Release Earnings on Friday

PAVmed (NASDAQ:PAVM) is anticipated to post its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect PAVmed to announce earnings of ($0.63) per share and revenue of $0.0480 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 8:30 AM ET.

PAVmed (NASDAQ:PAVM) last issued its earnings results on Thursday, May 14th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.48). PAVmed had a negative net margin of 21,914.12% and a negative return on equity of 146.19%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.07 million. On average, analysts expect PAVmed to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

PAVmed Stock Down 10.6%

PAVM stock opened at $4.21 on Thursday. The stock’s 50 day simple moving average is $5.19 and its 200 day simple moving average is $7.62. PAVmed has a fifty-two week low of $3.85 and a fifty-two week high of $28.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.02. The company has a market cap of $4.21 million, a P/E ratio of -0.11 and a beta of 0.54.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PAVM shares. Ascendiant Capital Markets reduced their price objective on PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $56.00.

Institutional Investors Weigh In On PAVmed

An institutional investor recently raised its stake in PAVmed stock. Jane Street Group LLC boosted its holdings in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the quarter. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. 19.93% of the stock is currently owned by institutional investors and hedge funds.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.